Ridaforolimus
PreclinicalSmall molecule
Merck & Co.Ridaforolimus is a small molecule that works as a Serine/threonine-Protein Kinase MTOR Inhibitor.[2] It is being investigated across 1 indication, with its most advanced program in Preclinical.[1]
Ridaforolimus is one of 7 small molecule programs targeting Coronary Stenosis. It is currently in Preclinical.
1
Indications
33
Total Trials
0
Active Trials
6
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Coronary Stenosis
#DrugCompanyPhaseTrials
1Bayer Aspirin
BayerApproved
Isordil
AstraZenecaApproved
Victoza
Novo NordiskApproved
Adenocard
AstellasApproved
Definity
MMicrovascular Therapeutics, LLC
Preclinical
Ridaforolimus
Merck & Co.Preclinical
Optison
GGE Healthcare
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Advanced Cancer4 trials
Breast Cancer4 trials
Endometrial Cancer2 trials
Prostate Cancer2 trials
17 more indications
Soft Tissue Sarcoma2 trials
Advanced Solid Tumors2 trials
Head Neck Cancer1 trial
Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer
Terminated·—·Phase 1·NCT01212627·12 enrolled
Relapsed or Refractory Hematologic Malignancies1 trial
Advanced Malignancies1 trial
Treatment1 trial
Advanced Sarcoma1 trial
Advanced Cancers1 trial
Maximum Tolerated Dose1 trial
Solid Tumors1 trial
Endometrial Carcinoma1 trial
Lymphoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ridaforolimus. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Serine/threonine-Protein Kinase MTOR Inhibitor[2]
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company